Decoding the language of cells to design better therapies for patients.
The promise of CAR-T therapy is immense. Yet, the path from bench to bedside remains a high-risk gamble. Unpredictable and life-threatening toxicities like Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are major barriers to its widespread adoption.
Q-Immune's mission is to solve this core challenge. We are building the critical "bench to bedside to bench" validation loop that the industry has been missing. Our platform combines high-throughput multiplex proteomics and AI to unlock a therapy’s functional blueprint, moving beyond traditional assays to capture the dynamic signaling networks that predict a therapy’s safety and efficacy. By translating this complex cellular language into actionable biosignatures, we are transforming CAR-T from a last resort into a predictable, safe, and widely accessible treatment for all.
Predicting Therapeutic Performance from a Cell’s Functional Blueprint
OUR APPROACH
The most significant barrier to the widespread adoption of next-generation cell therapies is not a lack of innovation, but a lack of predictability. Standard preclinical assays and in vitro models frequently fail to anticipate a therapy's true performance in patients, particularly for severe toxicities like Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). This gap between preclinical promise and clinical reality creates immense financial risk for developers and logistical hurdles for hospitals.
Q-Immune’s platform is designed to close this gap. We generate the high-resolution, functional data needed to move beyond traditional assumptions. By directly measuring the dynamic protein interaction networks within living cells, our technology provides an unparalleled view into how design choices translate into a therapy's clinical behavior. This proprietary data fuels our predictive models, allowing us to generate a validated "biosignature" that accurately forecasts a therapy's safety and efficacy before it reaches the patient. This unique capability allows our partners to de-risk and accelerate the development of high-impact cellular medicines.
OUR TECHNOLOGY
QMI + AI
A Predictive Platform for Cellular Therapies
Our platform combines our proprietary Quantitative Multiplex co-Immunoprecipitation (QMI) assay with a powerful AI-driven analytical engine. This synergistic approach allows us to move beyond simply observing cellular behavior by directly measuring the dynamic protein interaction networks within living cells. We convert this functional cellular blueprint into a definitive, actionable biosignature, providing an unparalleled view into how a therapy's molecular profile dictates its clinical performance.
Our technology is the only platform that can directly link a therapy’s intracellular signaling with its patient outcomes. We operate in a continuous "bench to bedside to bench" loop. The high-resolution data generated by our QMI assay is the foundation for our predictive models. By decoding the complex protein signaling cascades, we can generate a biosignature that accurately forecasts a therapy's safety and efficacy before it reaches the patient. This unique capability allows our partners to de-risk and accelerate the development of high-impact cellular medicines.